The R & D investment of 8.7 million yuan, Tonghua Dongbao xigliptin metformin tablets (Ⅱ) registration application accepted

On April 3, Tonghua Dongbao Pharmaceutical Co., Ltd issued an enterprise announcement that its company received the acceptance notice of the application for registration of xigliptin metformin tablets (Ⅱ) on April 2 The State Drug Administration reviewed the application for registration of the above drugs and decided to accept it Sitagliptin phosphate is a kind of highly selective DPP-4 small molecule inhibitor Its hypoglycemic mechanism is completely different from other hypoglycemic drugs It does not directly stimulate the islets of Langerhans, but through promoting the secretion of incretin in the intestines to achieve flexible control of insulin secretion It is called "intelligent" hypoglycemic drug Metformin can reduce the glucose and glucose produced by the liver The absorption of less glucose in the intestine can also improve the insulin sensitivity of the body by increasing the intake and utilization of glucose in the peripheral tissues, which is the first-line drug recommended by the current diabetes medication guidelines The research shows that the combination of sitagliptin phosphate and metformin can control blood glucose more effectively and stably The compound preparation of sitagliptin metformin tablets developed based on this can provide two convenient preparations in one tablet, which can be used for type 2 diabetes patients who are still under control of blood glucose after metformin single drug treatment or are receiving the combined treatment of both Cigliptin metformin tablets (II) were originally developed by mesardon, and were listed in the United States in March 2007 for oral treatment of type 2 diabetes The next year, cigliptin metformin tablets were approved for listing in the European Union In 2012, cigliptin metformin tablets were approved for import by China, with the trade name of zenoda ® According to Merck's annual report, the global sales of cigliptin metformin tablets (II) reached US $2.228 billion, an increase of 1.33% over 2017 In addition, according to the pharmaceutical intelligence data, at present, only the original research enterprise varieties are listed in the domestic market Although no generic drugs have been listed yet, the application for listing of xigliptin metformin tablets of Guangdong Dongguang Pharmaceutical Co., Ltd and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd has been accepted, and Guangdong Dongyang Pharmaceutical Co., Ltd is the first evaluated variety This application for registration of Tonghua Dongbao xigliptin metformin tablets (II) has been accepted To join the fierce competition Data source: Pharmaceutical intelligence data, enterprise announcement statement: This article is the integration content, the point of view only represents the author, does not represent the position of pharmaceutical intelligence network, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.